Can venetoclax/venetoclax and azacitidine only extend life?

The combination of Venetoclax and Azacitidine can be used to treat patients with high-risk refractory acute myeloid leukemia (AML). This combination treatment has been proven to significantly extend the progression-free survival and overall survival of patients, but it does not cure the disease.

Venetoclax is aBCL-2 inhibitor that promotes cell apoptosis by inhibiting the BCL-2 protein in leukemia cells. Azacitidine is a cytotoxic drug that can be a nucleotide analog that can inhibit the proliferation and differentiation of bone marrow hematopoietic stem cells, thereby improving the patient's anemia symptoms. However, for some patients, even if they receive this combination treatment, they need to be evaluated and judged based on the patient's specific situation. This is because factors such as the patient's age, health status, comorbidities, etc. will also affect the treatment effect and the patient's survival. Taken together, the combined treatment of venetoclax plus azacitidine can not only prolong the survival of patients, but also improve the prognosis of AML patients.

The original drug of Venekra has been launched in China and has been included in Class B medical insurance. The price of 100mg*14 tablets per box may be around 2,000 RMB, while the Turkish version of the original drug sold overseas, with the specification of 100mg*112 tablets, costs more than 10,000 RMB per box (the price may fluctuate due to the exchange rate). There are also cheaper generic drugs of Venacla sold overseas. Their pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 100mg*120 tablets produced by a Bangladesh pharmaceutical factory is more than 4,000 yuan per box (the price may fluctuate due to the exchange rate).